Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.99%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.03%
#4 clBTC clBTC +12.26%
#5 OpenEden OpenEden +10.90%
#6 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.95%
#7 MarsCoin MarsCoin +8.78%
#8 Mantle Staked Ether Mantle Staked Ether +8.43%
#9 Mantle Restaked ETH Mantle Restaked ETH +8.23%
#10 Akedo Akedo +8.03%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Synairgen plc Synairgen plc

Synairgen plc

SNG
株式のランク #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
株価
$0.01292666
最終同期: 2025-04-08
時価総額
$157.54K
変化（1日）
6.84%
変化（1年）
0.00%
国
GB
取引 Synairgen plc (SNG)

カテゴリー

Healthcare
Synairgen plc（SNG）の収益
Jun 2024 時点の収益 TTM: 0.00
Synairgen plc の最新の財務報告によると、現在の収益 (TTM) は 0.00 です。2022 年には 0.00 の収益があり、これは 2021 年の 0.00 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Synairgen plc の収益履歴（2004 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 -100.00%
2018 $133.74 -98.03%
2017 $6.79K 0.00%
2016 0.00 -100.00%
2015 $36.84 -99.45%
2014 $6.68K 0.00%
2013 0.00 0.00%
2012 0.00 -100.00%
2011 $248.65K 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 $156.44K 3.46%
2006 $151.21K -58.23%
2005 $361.99K 143.32%
2004 $148.77K 0.00%
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE